Welcome to our dedicated page for Gentex SEC filings (Ticker: GNTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Gentex Corporation's SEC filings document recurring financial-reporting, governance and capital-allocation disclosures for an operating technology supplier. Recent Form 8-K reports furnish quarterly and annual earnings releases, including net sales, margins, operating income, share repurchases, and separate references to core Gentex results and VOXX contributions after the completed acquisition.
Proxy materials cover board elections, shareholder voting matters, executive compensation, equity awards and related governance disclosures. The filing record frames Gentex's public-company reporting around its digital vision, connected car, dimmable glass, fire protection, medical device and consumer electronics businesses.
KENNEDY JOHN C reported acquisition or exercise transactions in this Form 4 filing.
GENTEX CORP director John C. Kennedy reported an equity award of 5,626 shares of Common Stock. The shares were granted at no cash cost to him as a compensation award and will vest 100% one year from the grant date. Following this grant, he holds 5,626 shares directly.
GENTEX CORP director John C. Kennedy has filed an initial insider ownership report on Form 3. The filing lists his position in the company’s Common Stock as zero shares following the reported date of May 21, 2026, and shows no buy or sell transactions.
Zang Ling reported acquisition or exercise transactions in this Form 4 filing.
Gentex Corp director Ling Zang reported an equity award of 5,626 shares of Common Stock. The shares were granted at no cost as a compensation award and will vest 100% one year from the grant date. Following this grant, Zang directly holds 35,599 Gentex shares.
WALKER BRIAN C reported acquisition or exercise transactions in this Form 4 filing.
GENTEX CORP director Brian C. Walker received a stock award of 5,626 shares of common stock as equity compensation. The shares were granted at no cash cost and will vest 100% one year from the grant award date. Following this award, Walker directly holds 29,831 common shares.
Starkoff Kathleen reported acquisition or exercise transactions in this Form 4 filing.
GENTEX CORP director Kathleen Starkoff reported receiving a stock award of 5,626 shares of Common Stock as a compensation-related grant. The shares were awarded at no cash cost and increase her direct holdings to 36,770 shares following the transaction. According to the disclosure, the entire award vests 100% one year from the grant award date, meaning she will gain full ownership after the one-year vesting period.
GENTEX CORP director Richard O. Schaum reported an equity award of 5,626 shares of Common Stock, received at a price of $0.00 per share as a grant or award acquisition. These shares vest 100% one year from the grant award date. Following this transaction, Schaum directly holds 87,069 shares.
Pink Billy reported acquisition or exercise transactions in this Form 4 filing.
GENTEX CORP director Billy Pink reported receiving an equity award of 5,626 shares of Common Stock. The award was granted at a stated price of $0.00 per share as a compensation grant. According to the footnote, these shares vest 100% one year from the grant award date. Following this award, Pink directly holds 15,329 shares of Gentex common stock.
DEUR GARTH reported acquisition or exercise transactions in this Form 4 filing.
GENTEX CORP director Garth Deur received a grant of 5,626 shares of Common Stock as a compensation award. The award was reported at a price of $0.00 per share, indicating it is not an open-market purchase but a share grant. Following this transaction, his directly held position increased to 20,045 shares of Common Stock. A footnote explains that these granted shares vest 100% one year from the grant award date, meaning he will gain full ownership rights to the entire award after that one-year vesting period.
BROWN LESLIE L reported acquisition or exercise transactions in this Form 4 filing.
GENTEX CORP director Leslie L. Brown received a grant of 5,626 shares of Common Stock, which vest 100% one year from the grant date. After this award, Brown directly holds 41,988 shares. This is a compensation-related equity grant rather than an open-market purchase.
Gentex Corp director Brian C. Walker reported an open-market sale of 5,939 shares of Gentex common stock at an average price of $22.9752 per share. After this transaction, he directly owns 24,205 Gentex shares, indicating he retains a meaningful continuing stake in the company.